StockTipsArenaBeta

BUY Aurobindo Pharma — Kush Bohra

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byKush BohraHorizon: NA (inferred Intraday)1 Sept 2026, 8:48 am ISTvia NDTV Profit (Live)

Entry₹1,700Inferred
Target₹1,768
Total upside +4.00% (call closed)
Stop loss₹1,640-3.53% risk
At expiry₹1,678.11 Sept 2026, 3:05 pm
Expired-1.29%
Follow Kush Bohra for new calls(17% target hit, 23 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 1 Sept 2026
4 supporting2 neutral1 opposing
Supports the BUY call (4)

Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD

NewsEt-Markets·31 Aug · today

(opens in new tab)

2 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·1 Sept · today

Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus® in the US. This product is used to treat asthma and COPD.

NSE · Press Release·31 Aug · yesterday

(opens in new tab)

Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus in the US. This marks the first product from Aurobindo's inhalation pipeline to be commercialized in

BSE · Company Update·31 Aug · yesterday

(opens in new tab)
Neutral / worth noting (2)

Aurobindo Pharma Ltd's wholly owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly owned subsidiary named Ávogent Lifesciences Private Limited.

BSE · Company Update·1 Sept · today

(opens in new tab)

Aurobindo Pharma’s API plant gets three US FDA observations after inspection

NewsCnbc-Tv18·28 Aug · 3d ago

(opens in new tab)
Weighs against the BUY call (1)

USFDA Issues Three Observations To Aurobindo Pharma Arm's Facility In Andhra

NewsNdtv-Profit·28 Aug · 3d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Kush Bohra

Every call and its outcome